Effect of Dapagliflozin on HbA1c in Type 2 Diabetics: A Descriptive Prospective Uncontrolled Before and After Study

Authors

Abstract

Objective: To determine the efficacy of Dapagliflozin and its effect on HbA1c in Type 2 Diabetic patients.

Methods

We had conducted our descriptive study in the outdoor patient department of Holy Family Hospital, Rawalpindi. Hundred, Type 2 diabetic patients of both genders were enrolled through consecutive sampling to assess the efficacy of Dapagliflozin, an SGLT2 inhibitor in a Pakistani population. Those patients with HbA1c of ≥ 7% who had fulfilled our inclusion criteria were given Dapagliflozin 10mg as either monotherapy or add-on therapy. HbA1c, BP, and body weight were noted at the start of drug therapy and after 12 weeks of drug use. The primary endpoint was ≥ a 10% relative percentage reduction of HbA1c after 12 weeks.

Results

 Out of 100 subjects there were 40 males and 60 females in our sample. The average age of the patients was 49.37±11.38 years. Dapagliflozin was given as a monotherapy to only two patients and others as an add on the drug. The average relative percent reduction after 12 weeks of treatment in HbA1c was 11.68±6.20. The sample results showed that the drug Dapagliflozin is effective for 62% of patients hence based on the sample results we conclude that the Dapagliflozin is effective against type 2 diabetics in our population for at least 53% of patients with a p-value of 0.034.

Conclusion

 Over the period of 12 weeks, Dapagliflozin has shown a significant reduction in HbA1c and body weight of Type 2 diabetics in the Pakistani population. Once-daily dosing and a low rate of hypoglycemia make it a cost-effective and safe drug as well.

Keywords:

Hb A1c, SGLT-2 inhibitors, Dapagliflozin.

Published

2025/06/05

Issue

Vol. -issue 2

This work is licensed under a Creative Commons Attribution-Non-Commercial 4.0 International License .

This is an open-access journal and all the published articles / items are distributed under the terms of the  Creative Commons Attribution BY-NC 4.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments psimjournal@gmail.com